ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 109 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2016. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $559,514 | +5417.3% | 252,038 | +6560.6% | 0.00% | – |
Q1 2024 | $10,141 | -10.4% | 3,784 | 0.0% | 0.00% | – |
Q4 2023 | $11,314 | +205.1% | 3,784 | 0.0% | 0.00% | – |
Q3 2023 | $3,708 | -62.6% | 3,784 | -47.0% | 0.00% | – |
Q2 2023 | $9,920 | +6178.5% | 7,137 | -92.8% | 0.00% | – |
Q1 2023 | $158 | -72.7% | 99,651 | +7.4% | 0.00% | -100.0% |
Q4 2022 | $578 | -99.9% | 92,828 | +8.4% | 0.00% | 0.0% |
Q3 2022 | $574,000 | +19.1% | 85,612 | +13.1% | 0.00% | 0.0% |
Q2 2022 | $482,000 | +93.6% | 75,713 | +40.9% | 0.00% | – |
Q1 2022 | $249,000 | +59.6% | 53,717 | +72.5% | 0.00% | – |
Q4 2021 | $156,000 | -59.1% | 31,133 | -1.5% | 0.00% | -100.0% |
Q3 2021 | $381,000 | -45.2% | 31,612 | -3.9% | 0.00% | 0.0% |
Q2 2021 | $695,000 | -22.8% | 32,878 | +2.5% | 0.00% | 0.0% |
Q1 2021 | $900,000 | -1.0% | 32,071 | -8.2% | 0.00% | 0.0% |
Q4 2020 | $909,000 | -28.1% | 34,947 | +2.8% | 0.00% | -50.0% |
Q3 2020 | $1,264,000 | -43.5% | 33,999 | -22.0% | 0.00% | -50.0% |
Q2 2020 | $2,238,000 | +86.0% | 43,609 | +14.3% | 0.00% | +33.3% |
Q1 2020 | $1,203,000 | -48.2% | 38,147 | -2.1% | 0.00% | -25.0% |
Q4 2019 | $2,323,000 | +75.5% | 38,951 | +7.8% | 0.00% | +100.0% |
Q3 2019 | $1,324,000 | -20.7% | 36,117 | +0.6% | 0.00% | -33.3% |
Q2 2019 | $1,670,000 | +33.2% | 35,907 | +15.0% | 0.00% | +50.0% |
Q1 2019 | $1,254,000 | -13.7% | 31,227 | -1.1% | 0.00% | -33.3% |
Q4 2018 | $1,453,000 | +50.6% | 31,583 | +45.2% | 0.00% | +50.0% |
Q3 2018 | $965,000 | +6.7% | 21,747 | -5.7% | 0.00% | 0.0% |
Q2 2018 | $904,000 | -27.3% | 23,061 | +34.1% | 0.00% | -33.3% |
Q1 2018 | $1,244,000 | +5.3% | 17,194 | -4.1% | 0.00% | +50.0% |
Q4 2017 | $1,181,000 | +15.0% | 17,934 | -12.5% | 0.00% | 0.0% |
Q3 2017 | $1,027,000 | +19.7% | 20,500 | +10.6% | 0.00% | 0.0% |
Q2 2017 | $858,000 | +26.7% | 18,540 | -3.3% | 0.00% | 0.0% |
Q1 2017 | $677,000 | +230.2% | 19,180 | +17.4% | 0.00% | +100.0% |
Q4 2016 | $205,000 | -14.6% | 16,334 | -5.8% | 0.00% | 0.0% |
Q3 2016 | $240,000 | +41.2% | 17,336 | +0.9% | 0.00% | 0.0% |
Q2 2016 | $170,000 | -25.8% | 17,186 | +27.0% | 0.00% | 0.0% |
Q1 2016 | $229,000 | -23.4% | 13,529 | +0.6% | 0.00% | 0.0% |
Q4 2015 | $299,000 | +4.9% | 13,449 | +11.4% | 0.00% | 0.0% |
Q3 2015 | $285,000 | -69.6% | 12,074 | +5.1% | 0.00% | -66.7% |
Q2 2015 | $939,000 | +91.6% | 11,485 | +117.1% | 0.00% | +200.0% |
Q1 2015 | $490,000 | – | 5,290 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
RA Capital Management | 704,701 | $24,883,000 | 3.05% |
Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
FT Options LLC | 22,834 | $806,000 | 1.06% |